CD79A and B-cell non-Hodgkin lymphoma: Two striking examples of such interaction were recently described in B-cell lymphomas: in WM, patients with MYD88L265P and CXCR4WT status showed the highest response rate to ibrutinib when compared to MYD88L265PCXCR4MUT and MYD88WTCXCR4WT patients [46]; in DLBCL, tumors with CD79A/BWTMYD88MUT did not respond to ibrutinib, whereas CD79A/B MUTMYD88MUT, CD79A/BWTMYD88WT, and CD79A/BMUTMYD88WT tumors did [44].